# A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

> **NCT03758339** · PHASE1 · COMPLETED · sponsor: **Cascadian Therapeutics Inc.** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** tucatinib

## Key facts

- **NCT ID:** NCT03758339
- **Lead sponsor:** Cascadian Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-30
- **Primary completion:** 2018-01-30
- **Final completion:** 2018-01-30
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758339, "A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03758339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*